Skip to content

Long-Term Effects of Sucontral(TM) on Mild and Moderate Cases of Diabetes Mellitus (Type 2)

Controlled Clinical Trial on Long Term Effects of Hintonia Latiflora Extract in Mild to Moderate Type 2 Diabetes

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00315718
Enrollment
10
Registered
2006-04-19
Start date
2002-06-30
Completion date
2005-06-30
Last updated
2006-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Keywords

Hintonia latiflora extract, Diabetes mellitus type 2, HbA1c, Safety, Liver function tests

Brief summary

In patients with diabetes mellitus type 2 stably adjusted to diet long-term intake of aqueous-ethanolic extract from Hintonia latiflora over more than 12 months leads to a statstically significant amelioration of parameters of glycaemic control (HbA1c, postprandial and fasting glucose) not acchievable with diet alone. As safety parameters, liver function tests and cardiovascular parameters are to be monitored. Adverse events are to be monitored.

Detailed description

Objective: To evaluate the long term effects of an aqueous-ethanolic extract from the bark of Hintonia latiflora (1:4.5, extraction medium 32% ethanol) in mild to moderate cases of type II diabetes, especially on parameters of glycaemic control and safety. Research Design and Methods: The trial was carried out as a controlled single-centre open study. 30 patients stably adjusted to diet were treated with the study medication (3 x 2 ml/day before meals) for up to 36 months. Efficacy parameters were HbA1c and fasting and postprandial serum glucose. As parameters for safety, liver function tests, cardiac functions and adverse events were assessed. Results: All three efficacy parameters improved significantly, and the parameters of glycaemic control remained stable for the study duration of 36 months. As compared to baseline, after 6 months and 18 months of therapy mean fasting glucose was reduced by 23.9 and 21.9 % (1.8 mmol and 2.0 mmol in absolute values). Mean postprandial glucose was reduced by 24.4 and 16.5 % (2.4 and 2.0 mmol in absolute values), and the mean HbA1c was decreased by 10.4 and 12.4 % (0.76 and 1.04% in absolute figures). Improvement was maintained after 18 months. Tolerability was excellent. No hypoglycaemic reactions occurred. No adverse effects or change in cardiac and liver function tests were observed. There was a tendency towards decreasing triglyceride and total cholesterol levels.

Interventions

DRUGExtract from Hintonia latiflora bark

Sponsors

Harras Pharma Curarina GmbH
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
45 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Mild to moderate Diabetes mellitus type 2 stable adjusted to diet * Minimum duration of diabetic complaints 1 year * Fasting serum glucose 7-14 mmol/l * HbA1c max. 12% * Written consent

Exclusion criteria

* Hepatic impairment * Renal impairment * Pregnancy

Design outcomes

Primary

MeasureTime frame
HbA1c values

Secondary

MeasureTime frame
Postprandial blood glucose
Fasting blood glucose
General vegetative symptoms
BMI
Liver function tests (ALT, GGT, AP)
Serum lipids (triglycerides, cholesterol, HDL cholesterol)
Adverse drug reactions (narratives)
Blood pressure (systolic/diastolic)

Countries

Slovakia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026